Short communicationIncreased Deoxythymidine triphosphate (cas 18423-43-3) levels is a feature of relative cognitive decline

Add time:08/31/2019    Source:sciencedirect.com

Mitochondrial bioenergetics, mitochondrial reactive oxygen species (ROS) and cellular levels of nucleotides have been hypothesized as early indicators of Alzheimer's disease (AD). Utilizing relative decline of cognitive ability as a predictor of AD risk, we evaluated the correlation between change of cognitive ability and mitochondrial bioenergetics, ROS and cellular levels of deoxyribonucleotides. Change of cognitive abilities, scored at ages of approximately 20 and 57 was determined for a cohort of 1985 male participants. Mitochondrial bioenergetics, mitochondrial ROS and whole-cell levels of deoxyribonucleotide triphosphates were measured in peripheral blood mononuclear cells (PBMCs) from a total of 103 selected participants displaying the most pronounced relative cognitive decline and relative cognitive improvement. We show that relative cognitive decline is associated with higher PBMC content of deoxythymidine-triphosphate (dTTP) (20%), but not mitochondrial bioenergetics parameters measured in this study or mitochondrial ROS. Levels of dTTP in PBMCs are indicators of relative cognitive change suggesting a role of deoxyribonucleotides in the etiology of AD.

We also recommend Trading Suppliers and Manufacturers of Deoxythymidine triphosphate (cas 18423-43-3). Pls Click Website Link as below: cas 18423-43-3 suppliers

Prev:ORIGINAL ARTICLESimple salting-out method for DNA extraction from formalin-fixed, paraffin-embedded tissues
Next:Inhibition of the reverse transcriptase from HIV by 3′-azido-3′-Deoxythymidine triphosphate (cas 18423-43-3) and its threo analogue)